Grant of first POLB 001 cancer immunotherapy-induced CRS patent   Significant milestone for Poolbeg’s global intellectual property portfolio   31 March 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from IP Australia, the Australian patent office.   This represents the…

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board.   Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome…

TR-1: Standard form for notification of major holdings. Michael Kelly has increased his shareholding from 5.03% to 6.14% or 43,314,547 shares.

28 January 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Key conclusions from the paper include:   ·          POLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment following LPS challenge in healthy volunteers ·          POLB 001 was safe and well tolerated across…

18 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, publishes an end of year letter from the Company’s Executive Chair, Cathal Friel, providing an overview of the significant progress made by the Company in 2025 and outlook for 2026.   Dear Shareholders,   As 2025 draws to a close, we wanted to reflect on the substantial progress made by Poolbeg this…

Alan Green discusses: Poolbeg Pharmaceuticals #POLB Ajax Resources #AJAX Anglesey Mining #AYM with Justin at Breakout Capital Ventures

8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the POLB 001 TOPICAL trial is to feature in a groundbreaking cancer immunotherapy-induced cytokine release syndrome (“CRS”) research programme.   Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme supported by…

20 November 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza.   POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome…

  29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Highlights & Updates • Cash balance of £10.0 million as at 30 June 2025, including £4.865 million gross proceeds raised as part of an oversubscribed and upsized fundraise • Cash runway extended into 2027, supporting the delivery of multiple…

25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The…

TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Poolbeg Pharma plc 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for…

25 June 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that as announced  on 20 May 2025, Mr Cathal Friel, Executive Chair and PDMR of the Company, participated in the Fundraising subscribing for 4,000,000 new Ordinary Shares at a price of 2.5p per share (the Issue Price).  Following the AGM earlier this week, the New Ordinary Shares issued pursuant…

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that all resolutions put to shareholders at the Company’s Annual General Meeting and General Meeting (together, the “Meetings”) held earlier today were duly passed.  The voting results of the Meetings will be published on the Company’s website shortly: https://www.poolbegpharma.com/investors/documents/  Admission and Total Voting Rights Pursuant to the Company’s fundraising to raise total…

27 May 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (“CRS”).   The FDA grants orphan status to support the development of medicines for rare disorders affecting less than…

On this week’s Stockbox podcast with Alan Green, Mark Fairbairn and Dan Flynn, we discuss: URU Metals #URU Coinsilium #COIN Smarter Web UK #SWC Poolbeg Pharma #POLB

Result of upsized and oversubscribed BookBuild Offer ·      Conditionally raised gross proceeds of £150,000 from the upsized and oversubscribed BookBuild Offer ·      Total gross proceeds conditionally raised pursuant to the Fundraising therefore increased to £4.865 million ·      Use of net proceeds from the Fundraising: o  Phase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS) o  Oral GLP-1 proof-of-concept clinical trial o  Cash runway extended through to 2027 Poolbeg Pharma…

Poolbeg Pharma plc (AIM: POLB, ‘Poolbeg Pharma’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that, further to the announcement made on 20 May 2025 regarding the proposed BookBuild Offer (the “BookBuild Offer Announcement”), the BookBuild Offer is significantly oversubscribed and therefore the Company is increasing the number of BookBuild Offer Shares made available at the Issue Price to 6,000,000, which, if fully…

Poolbeg Pharma plc (AIM: POLB, ‘Poolbeg Pharma’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that, further to the announcement made earlier today regarding the Fundraising, it has conditionally raised gross proceeds of £4.715 million, including £3.370 million by way of a placing (the “Placing”) of 134,800,000 new ordinary shares of 0.02 pence each (the “Ordinary Shares”) in the capital of the Company,…

Results for the year ended 31 December 2024   20 May 2025- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces its audited results for the year ended 31 December 2024.  2024 Highlights • Cash balance of £7.8 million as at 31 December 2024, reflecting disciplined capital allocation to drive pipeline advancements • Cathal Friel appointed as Executive Chair to drive performance and seek…

20 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg’s Republic of Korea Immunomodulator II patent application providing protection to POLB 001 for the treatment of severe influenza to December 2038.   POLB 001 is a potent and selective p38 MAP…

Further to the 2.4 announcement on 2 January 2025 on the potential combination of Poolbeg Pharma (“Poolbeg” or the “Company”) and HOOKIPA Pharma Inc (“HOOKIPA”), the Board of Poolbeg announces that it was informed yesterday that HOOKIPA has terminated discussions on the proposed combination of the two companies.   Cathal Friel, Executive Chairman of Poolbeg, said: “We were surprised and disappointed to hear of HOOKIPA’s decision to withdraw from the combination discussions. Throughout this process,…

On 2 January 2025, HOOKIPA Pharma Inc. (“HOOKIPA”) and Poolbeg Pharma plc (“Poolbeg”) announced that they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg (the “Possible Offer” and the “2.4 Announcement”, respectively) to create a strong clinical-stage biopharmaceutical company focused on developing and commercialising innovative medicines for critical unmet medical needs, with a special focus on next-generation immunotherapies for the treatment of cancer and other serious diseases. Since then, the…

Further to the announcement on 2 January 2025 (the “2.4 Announcement”) and the update on the potential combination of Poolbeg and HOOKIPA announced on 7 January 2025, the following amendment has been made regarding Gilead Sciences Inc.’s (“Gilead”) participation in the proposed concurrent Fundraise. Gilead has indicated its intention to vote consistent with the HOOKIPA Board’s recommendation if a formal offer were to be made and to participate in the proposed concurrent Fundraise in an…

Further to the announcement on 2 January 2025 (the “2.4 Announcement”), the Boards of Poolbeg and HOOKIPA are pleased to confirm that significant HOOKIPA shareholder, Gilead Sciences Inc. (“Gilead”), has indicated its intention to vote consistent with the HOOKIPA Board’s recommendation if a formal offer were to be made and to participate in the proposed concurrent Fundraise, consistent with its current contractual obligations. Gilead owns 1,875,947 HOOKIPA common shares, representing 19.4% of HOOKIPA’s existing issued…

9 December 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces key insights from its poster presentation at the 66th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, San Diego, California. All doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome scores  POLB 001 treatment showed statistically significant reductions in key cytokines  Positive…

20 November 2024- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the US Patent Office has notified the Company of its official decision to grant Poolbeg’s US Immunomodulator I patent application. The claims cover POLB 001, and other p38 MAP kinase inhibitors, for the treatment of patients at risk of severe influenza after an…

6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that it will present a poster detailing POLB 001’s efficacy in reducing immunotherapy-induced CRS in an in vivo animal model, at the 66th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, taking place 7-10 December 2024 in San Diego, California. Poolbeg’s poster presentation will provide insights into the results…

Alan Green covers Clontarf Energy #CLON, Voyager Life (M3 Helium) #VOY & Poolbeg Pharma #POLB on this week’s Stockbox Research Talks

Poolbeg Pharma plc – Interim results for the six months to 30 June 2024   Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded Continued focus on high value programmes & partnerships to develop & commercialise assets Strong Balance Sheet – cash balance of £10.1m Experienced leadership team with track record of…

27 August 2024 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that Jeremy Skillington, PhD, Chief Executive Officer and David Allmond, Chief Business Officer will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference, being held on 9-11 September 2024 in New York and virtually. The presentation will be available to view…

26 July 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares (“Ordinary Shares”) from trading on the OTCQB Market due to low trading volume and the associated administrative requirements. The Company’s last day of trading on the OTCQB Market will be Monday 29 July 2024. Poolbeg…

Poolbeg Pharma #POLB was informed today that Michael Kelly’s shareholding has increased from 4.8% to 5.2% (26,039,455 shares)

2 July 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the Company has changed its registered address to 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.   Enquiries    Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO +44 (0) 207 183 1499 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)…

13 June 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that all resolutions put to shareholders at the Company’s Annual General Meeting held earlier today were duly passed.   Enquiries    Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO +44 (0) 207 183 1499 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) Geoff…

9 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, confirms that the Company’s Annual Report and Accounts for the period ended 31 December 2023 and the notice of Annual General Meeting (“AGM”) will be posted to shareholders today.   The 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of…

1 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that, further to its announcement on 20 March 2024, the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.   The claims cover a class of drugs (including POLB 001) for treating hypercytokinaemia (cytokine…

30 April 2024 – Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has appointed Shore Capital Stockbrokers Limited as its Joint Broker with immediate effect. Cavendish Capital Markets Ltd remains as the Company’s Nominated Adviser and Joint Broker alongside J&E Davy as Joint Broker. Enquiries   Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell,…

Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet’s Disease Novel therapeutic with Fast Track and Orphan Designation 30 April 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc,  for a nominal fee, to acquire…

30 April 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces its audited results for the year ended 31 December 2023. Financial & Corporate Highlights ·    Cash balance of £12.2 million as at 31 December 2023 ·    Industry veteran, Professor Brendan Buckley, appointed as Non-Executive Director ·    Recruitment of key management hires, former…

TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Poolbeg Pharma PLC 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification…

Notice of Allowance for Significant POLB 001 Patent in United States Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio   20 March 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator…

Poolbeg Pharma CEO Jeremy Skillington talks to Alan Green, and recaps on the developments at the company since last year. These include the strategic collaboration with a Nasdaq-Listed Biopharma Co to use Poolbeg’s oral delivery technology, the expansion of Poolbeg’s IP, and the appointment t of a number of key former Amryt Pharma executives, namely David Allmond, John McEvoy and Laura Maher. Jeremy highlights the recent progress with the flagship POLB 001 and its potential in…

22 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received notification that on 21 February 2024, Jeremy Skillington, Chief Executive Officer of the Company, purchased 154,764 ordinary shares at a price of 10.8 pence per share (the “Purchase”).   Following the Purchase, Jeremy holds 873,497 ordinary shares representing…

19 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received notification that on 19 February 2024, Cathal Friel, Executive Chairman of the Company, purchased 830,000 ordinary shares at a price of 11.68 pence per share (the “Purchase”).  Following the Purchase, Cathal holds 37,219,757 ordinary shares representing approximately 7.4…

15 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, “Poolbeg” or the “Company”), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Board role and the Remuneration Committee’s approval of the adoption of an Employee Performance Incentive Plan (“EIP”) for a number of the key senior management, to align medium and long term objectives with those of shareholders and to encourage…

Former Amryt team’s arrival supports increasing focus upon Rare and Orphan Diseases   12 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that independent research[i] [ii] conducted on behalf of Poolbeg confirms a >$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS as an orally delivered preventative therapy.…

Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion   Key highlights –      Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model –      Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS –      Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS –…

StockBox Research Talks – Alan Green and Mark Fairbairn Stock Picks for 2024 including #ARK, #AYM, #BRES, #ECR, #FCM, #KDNC, #MARU, #NEO, #PALM, #POLB, #PREM, #ONDO #REE, #SVML

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces the positive outputs from the lab-based analysis and successful prioritisation of the Respiratory Syncytial Virus (‘RSV’) drug targets and treatments identified as part of its artificial intelligence (‘AI’) led programme.   Poolbeg’s team of scientific experts have reviewed the comprehensive data package obtained from this lab-based…

11 December 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need and with a lack of treatment alternatives, announces key insights from its poster presentation at the prestigious, 65th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, San Diego.   The poster, which details POLB 001 as a potential therapy for Cytokine Release Syndrome (‘CRS’)…

30 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its Board of Directors. Patrick Ashe, Independent Non-Executive Director, will step down from the Board at the end of November. Eddie Gibson, Non-Executive Director will replace Patrick as Chair of the Audit & Risk Committee and Prof Brendan Buckley, Non-Executive Director…

21 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the Japanese Patent Office has notified the Company of its official decision to grant Poolbeg’s Immunomodulator II patent application. The claims cover the pharmaceutical composition of POLB 001 for treating severe influenza in a hospitalised patient in combination with antiviral compounds, further strengthening…

16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International Congress of Immunology (‘IUIS’), to be held 27 November – 2 December 2023 in Cape Town, South Africa. IUIS is the world’s…

9 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both Poolbeg and Amryt Pharma plc. Poolbeg intends to follow a similar strategic approach to Amryt…

3 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that an abstract detailing POLB 001’s promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at 65th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, to be held 9-12 December 2023 in San Diego, California.   The ASH Annual Meeting and Exposition…

  1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors and analysts on the POLB 001 Oncology Programme on Monday 6 November 2023 at 2:00pm – 3:30pm GMT via the Investor Meet Company platform.     The event will provide an update and greater detail on Poolbeg’s POLB 001 Oncology programme, which is…

26 October 2023 – (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that its Scientific Advisory Board (‘SAB’) has endorsed the influenza drug targets identified in its AI-led drug discovery programme.   Key highlights   ·      Prioritisation of influenza drug targets which have the highest likelihood of success ·      New potential collaborative routes to maximise the impact of the outputs identified ·      Ongoing discussions with…

Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform   Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology   Collaboration may expand to a full licensing agreement   17 October 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a strategic collaboration agreement…

29 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled. This favourably concludes this matter with the patent maintained as granted.   The Immunomodulator I European patent was…

20 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application.   The claims deemed allowable cover a p38 MAPK (mitogen-activated protein kinase) inhibitor for use in the treatment of severe influenza in human patients and strengthens the Company’s robust intellectual property…

19 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that the opposition to one of its European patents (Immunomodulator I) that was previously filed by a third party is to be withdrawn. In the pharmaceutical industry it is not unusual for patents to be challenged. The Immunomodulator I European patent was opposed by a third party in September 2021. Further to engaging…

13 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces its unaudited interim results for the six months to 30 June 2023.   Interim Results Highlights and Business Update ·    Strong cash balance of £14.1 million as at 30 June 2023 (31 December 2022: £16.2m) ·    Positive results from the POLB 001 LPS human challenge trial. The asset has the potential to…

Poolbeg CEO Jeremy Skillington talks to Alan Green in this August 2023 interview, and explains the company’s ‘capital light’ model that is giving the group a real market advantage. Jeremy then covers the developments this year with Poolbeg’s flagship POLB001 asset towards a blockbuster treatment for severe influenza, and the expansion of application into oncology and obesity. We then discuss joint ventures with AnaBio Technologies in the EncOVac consortium and the Cytoreason AI collaboration, before…

AI analysis of unique human challenge trial data provides unparalleled insights into influenza infection   Novel influenza drug targets identified faster and more cost-effectively using AI   29 June 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence (‘AI’) Programme with CytoReason. Poolbeg has been working with CytoReason since March…

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with high unmet medical needs, announces an update to its Oral Vaccine Programme following the award of non-dilutive grant funding by the Irish Government’s Disruptive Technologies Innovation Fund (“DTIF”) in November 2022, as part of the Poolbeg led EncOVac Consortium[1]. Having finalised the research plan and all consortium members completing the Consortium and Grant…

24 May 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee.   Professor Buckley is the former Chief Medical Officer of ICON plc, a medical graduate of University College Cork and a doctoral…

London, UK 30 March 2023 – Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF “Poolbeg” or the “Company”) a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022.   Financial & Corporate Highlights –       Well capitalised with a cash balance of £16.2m at year end –       Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress its…

Key highlights ·      Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia ·      Allows for use in combination with an antiviral agent ·      Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline   8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’),  a leading infectious disease focused biopharmaceutical company, announces that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO)…

Alan Green provides a SoTP valuation for Power Metal Resources #POW & covers Poolbeg Pharma #POLB on this week’s Stockbox Research Talks

2 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces the data readout from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions. POLB 001 was shown to be safe and well tolerated and had a potent effect…

Markets and Stocks January 2023 – Doc Holliday talks to Alan Green. We look at Doc’s new Twitter Spaces cast, before turning to stocks: 04:00 Avacta #AVCT | 06:00 Hvivo #HVO & Poolbeg Pharma #POLB | 08:15 – Longboat Energy #LBE / Energy stocks | 11:26 – Cadence Minerals #KDNC | 14:55 – Mining Companies | 17:40 – Argo Blockchain #ARB | 21:20 – Revolution Bars #RGB | 26:26 – Over the next few months |…

Key Highlights ·      Newly filed patent application to protect use of POLB 001 for new oncology indication ·    Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies ·      Patent application covers a method of use of all p38 inhibitors during CAR T cell therapy ·      Progressing towards trial initiation in CAR T cell patients in 2024   16 January 2023 – Poolbeg…

New Vox Markets Podcast #podcast with our CEO Alan Green discussing: – Poolbegb Pharma #POLB – Amryt Pharma (Nasdaq: #AMYT) – Georgia Capital #CGEO – Marula Mining #MARU https://www.voxmarkets.co.uk/articles/alan-green-talks-about-poolbeg-pharma-georgia-capital-marula-mining-b8602ad/

Key Highlights · POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo · A clear dose-response relationship was demonstrated                                                                 · Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported · Full data read-out expected in Q2 2023 following a final quality check of the unblinded data 9 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or…

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus (‘RSV’) artificial intelligence (‘AI’) Programme with OneThree Biotech, Inc.   Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked closely with OneThree to build a tailored AI approach that leverages Poolbeg’s unique RSV human challenge trial data in order to identify disease-relevant biological…

Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023 Prof Brendan Buckley joins Poolbeg’s Scientific Advisory Board to guide clinical development of technology Licence expands Poolbeg’s existing exclusive licence to AnaBio’s oral vaccine delivery technology Investor Meet Company presentation on 14 December 2022 at 5:30pm Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it has acquired an exclusive licence from…

12 December 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. Key highlights from the study: ·     No further clinical…

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that, further to its announcement in March 2022 , the construction of the computational artificial intelligence (AI) influenza disease model has been completed by CytoReason Limited (‘CytoReason’), indicating that it is on track to deliver outputs in Q2 2023. The model aims to unlock clinically meaningful insights into influenza infection…

17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30 November between 10am – 12:45pm.   The event, which will be chaired by Jeremy Skillington, Chief Executive Officer, will provide insights into a number of the Company’s growing pipeline…

15 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that ‘EncOVac’, a consortium led by Poolbeg Pharma, has been awarded €2.3m in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (‘DTIF’). Taking place over three years, the collaboration between Poolbeg Pharma, University College Dublin, Trinity College…

8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of Respiratory Syncytial Virus (‘RSV’). Following the completion of the build and optimisation of a tailored AI model…

21 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, announces that its management and business development team will be attending and presenting at a number upcoming partnering and investor events from October 2022 to January 2023.   Partnering events • BIO-Europe from 24-26 October 2022 at Leipzig Messe, Leipzig, Germany 04356 • Jefferies London Healthcare Conference from 15-17 November 2022 in London •…

6 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been notified that Chief Executive Officer, Jeremy Skillington, has purchased 718,733 ordinary shares of 0.02 pence each in the Company (“Ordinary Shares”) at a share price of 4.78 pence per share. Following the purchase, Jeremy Skillington’s beneficial interest in the Company is 718,733 Ordinary Shares, representing…

4 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, provides an update on the strengthening of its intellectual property (IP) position around POLB 001, a small molecule immunomodulator for the treatment of severe influenza.  The US Patent and Trademarks Office, after reviewing a patent application that is directed to the use of POLB 001 and its homologues…

Alan Green covers Poolbeg Pharma #POLB & Sovereign Metals #SVML on this week’s Stockbox Research Talks

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that further to the Option Agreement announced in December 2021, Poolbeg has signed an exclusive Licence Agreement with University College Dublin (UCD) through NovaUCD, the University’s knowledge transfer office, for a late preclinical stage vaccine candidate for Melioidosis, a disease for which there is no current approved vaccine available. The…

12 September 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in New York City, NY, USA.   Enquiries   Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO    +44 (0)…

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces its unaudited interim results for the six months to 30 June 2022. Financial & Operational Highlights • Well capitalised with a strong cash balance of £18.9m as at 30 June 2022 • Significant progress made on developing POLB 001, a treatment for severe influenza – LPS human challenge trial commenced…

31 August 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, will announce the Company’s interim results for the six months to 30 June 2022, on 6 September 2022.   Jeremy Skillington, Chief Executive Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on 6 September 2022 at 18:00 BST.…

Alan Green discusses #WTB Whitbread, #POLB Poolbeg Pharma & #FCM First Class Metals on the Vox Market Podcast Listen here

29 July 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effect. finnCap Ltd will continue to act as Nominated Adviser and Joint Broker alongside J&E Davy as additional Joint Broker.   – Ends – Enquiries Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO   +44 (0) 207 183 1499…

A landmark year for Poolbeg Pharma #POLB – Alan Green talks to CEO Jeremy Skillington, who takes us through what has been a very eventful year since the IPO. At 01:58 we discuss the flagship asset POLB 001, which reached a major milestone last week as it commenced a human challenge trial. At 05:00 Jeremy provides an overview of two collaborations in Artificial Intelligence and how Poolbeg will use these pioneering approaches to identify new treatments for…

20 July 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza. Key Highlights: • Clinical trial activities will formally…

  Poolbeg featured in the @MorningstarInc following yesterdays announcement on the completion of build 7 optimisation of our #AI model for RSV #data, the first time AI used to model #RSV with complete longitudinal #disease data. Link below to read in full: https://www.morningstar.co.uk/uk/news/AN_1656323268845373200/poolbeg-pharma-ai-model-of-respiratory-syncytial-virus-starts-analysis.aspx

27 June 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that, further to its announcement in February 2022 , Artificial Intelligence (‘AI’) partner OneThree Biotech , Inc., has completed the build and optimisation of a tailored AI model of Poolbeg’s Respiratory Syncytial Virus (‘RSV’) human challenge data and can now commence its analysis, with results expected in Q4 2022.   Key Highlights:…

  The @McKinsey’s #biotech #investment themes article highlights “insufficient number of high-quality data”a limitation to AI #drugdiscovery #POLB‘s #AI programmes have access the world’s largest data & #biobank of high-dimensional #disease progression data The @McKinsey’s #biotech #investment themes article highlights “insufficient number of high-quality data”a limitation to AI #drugdiscovery#POLB's #AI programmes have access the world's largest data & #biobank of high-dimensional #disease progression datahttps://t.co/E5rwZlIqu1 — Poolbeg Pharma (@PoolbegPharma) June 14, 2022

26 May 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections.   POLB 001 The USPTO granted a patent for the majority of Poolbeg’s claims…

TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Poolbeg Pharma PLC 1b. Please indicate if the issuer is a non-UK issuer   (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate…

Alan Green covers Amaroq Minerals #AEXG and Poolbeg Pharma #POLB on this week’s Stockbox Research Talks

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces an update on its lead asset, POLB 001, a small molecule immunomodulator which aims to address a significant unmet need in severe influenza. The Company has signed a contract for GMP manufacturing, ensuring ample supply of GMP grade POLB 001 for use in its upcoming LPS human challenge clinical trial, due…

11 May 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz, Austria, as it develops a Melioidosis vaccine candidate.  Poolbeg currently holds an option from University College Dublin to licence a late pre-clinical stage Melioidosis vaccine…

Today Poolbeg Pharma #POLB will be attending the LSX Leaders event & CEO Jeremy Skillington will be presenting the Poolbeg Pharma story, including how we are aspiring to become a one-stop-shop for Big Pharma seeking mid-stage products to license or acquire.  

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces the results of the proposal from a number of New Investors to purchase shares from distribution in specie shareholders ahead of the end of the lock-up period. As published via an RNS on 11 April 2022 , the Company sourced a number of New Investors that offered to purchase up…

– Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, provides an update on the strengthening of its intellectual property (IP) for its asset POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections.   In January this year, Poolbeg secured an exclusive licence for the dual antiviral prophylactic and therapeutic candidate, which is being developed as POLB…

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that a number of new investors (“New Investors”) have expressed interest in acquiring up to £1.6m of Poolbeg Pharma plc shares which are currently locked-up and held in trust by Croft Nominees Limited (“Croft”) as a result of the distribution in specie from Open Orphan plc (“Open Orphan”) on 18…

4 April 2022 – Poolbeg Pharma  (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital  light clinical model,  announces that at the Annual General Meeting held at 11:00am today, all resolutions were duly passed with in excess of  99.9% approval. -Ends-   Enquiries   Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO   +44 (0) 207 183 1499 finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard…

31 March, 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’) announces that it has signed a Clinical Trial Agreement with the Centre for Human Drug Research (CHDR) in the Netherlands for the completion of a bacterial lipopolysaccharide (‘LPS’) human challenge study of POLB 001, which is due to commence in June 2022. First results are expected before the end of 2022 at which point the Company aims to rapidly monetise by…

30 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that trading in the Company’s Ordinary Shares of nominal value of £0.02 each (“Ordinary Shares”) will commence today on the OTCQB Venture Market in the United States. The Company’s OTCQB shares will have the ticker: POLBF. There is no associated capital raise with this cross trading and Poolbeg’s…

  AI programme yields novel RSV drug targets Artificial intelligence programme yields multiple novel RSV drug targets First time AI has been used to identify disease targets in RSV   8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with partner OneThree Biotech , Inc. through…

  Poolbeg Pharma PLC #POLB – AI programme yields novel RSV drug targets Artificial intelligence programme yields multiple novel RSV drug targets First time AI has been used to identify disease targets in RSV 8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with…

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £5m respiratory syncytial virus (“RSV”) human challenge study contract with a European biotechnology company (“European biotech”) to test its intravenous antiviral candidate, using the hVIVO RSV Human Challenge Study Model.   The study is expected to commence…

24 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has signed a deal with CytoReason, a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples.   The partnership will harness the insights of Poolbeg’s unique repository…

When will I receive my share certificate? The Poolbeg Pharma shares received are subject to a lock-up period that ends on 19 April 2022. Within 14 days of that date, shareholders will be sent a certificate for their distribution in specie shares. Shareholders will then have the option to dematerialise the shares and hold via CREST. If your Open Orphan plc shares that gave rise to the entitlement to the distribution in specie shares are…

Alan Green covers #POLB Poolbeg Pharma, #NTOG Nostra Terra O&G and #MNRG MetalNRG on the Vox Market Podcast Listen to the podcast here

  POLB’s CEO Jeremy Skillington & One Three Biotech‘s co-founder & COO Brad Pryde catch up with @proactive_UK to discuss the recent AI deal to identify new drugs & treatments for RSV.

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model , announces that its Annual Report and Accounts for the period ended 31 December 2021, a notice of the Annual General Meeting (“AGM”) 2022 and voting proxy form have been posted to shareholders. Persons whose distribution in specie shares are held in trust by Croft Nominees Limited (“Croft”) have also received a Voting…

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) announces its audited results for the period ended 31 December 2021. These results follow the Company’s spin-out from Open Orphan plc and the subsequent listing on the AIM market of the London Stock Exchange in July 2021.   Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a capital light model which is looking to develop multiple products faster and more cost effectively than the conventional biotech model. Poolbeg…

Co-founder & #COO of One Three Biotech, Brad Pryde catches up with brr mediauk on the #AI Deal with #POLB Poolbeg Pharma to identify new #drugs & treatments for #RSV.     https://www.youtube.com/watch?v=TnKrI6xCt4s&ab_channel=PoolbegPharma

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model , will announce its results for the period ended 31 December 2021 on Thursday 3 March 2022. The Company will be hosting an online presentation for investors on the same day, at 6:00pm GMT on the Investor Meet Company platform.   The presentation is open to all existing and potential shareholders. Investors can register to attend here:…

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an agreement with OneThree Biotech, Inc . a biology-driven artificial intelligence (‘AI’) company, to identify new drug targets and treatments for Respiratory Syncytial Virus (‘RSV’).   Under the terms of the transaction and as aligned with Poolbeg’s strategy, OneThree Biotech’s state-of-the-art AI analysis tools will identify drug assets which target immune-response pathways, have a higher probability…

Artificial Intelligence gives unique insight to #drug discovery by spotting links that humans miss. These links identify new #drugs likely to succeed in clinic. In a crowded industry, #AI gives #POLB the edge Learn more: https://poolbegpharma.com/pipeline/further-assets/…

CEO of Poolbeg Pharma, will be presenting at next weeks London South East webinar. They look forward to providing updates on recent Company news. Register to attend: https://us02web.zoom.us/webinar/register/1716431929653/WN_ZJVzMqdWTgWYBetrouIuFg

  CEO Of Poolbeg Pharma caught up with @Proactive_UK to discuss our their vaccine discovery platform & rapidly expanding pipeline #POLB 001 POLB 002 POLB 003 Oral Vaccine Discovery Platform AI Powered Drug Programme Vaccine Discovery Platform PredictViral  

31 January, 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, confirms that it has signed the licence to AnaBio Technologies’ (‘AnaBio’) microencapsulation and nanoencapsulation technologies to develop an oral vaccine delivery platform. This follows the binding term sheet announced on 16 December 2021. This licence provides Poolbeg with exclusive access to AnaBio’s microencapsulation and nanoencapsulation technologies for use in the…

Alan Green CEO of Brand Communications talks about: Revolution Bars #RBG Blencowe Resources #BRES  Poolbeg Pharma #POLB https://www.voxmarkets.co.uk/articles/alan-green-discusses-revolution-bars-blencowe-resources-poolbeg-pharma-ed98e6d/

Poolbeg Pharma #POLB – CEO Jeremy Skillington talks to Alan Green, and explains the ‘capital light’ model used by the company to grow the business. Jeremy talks about the three licensing deals signed by the company over the past few months, including the option agreement to licence MelioVac, the tie up with AnaBio Technologies and today’s announcement that Poolbeg has in-licenced a first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick. Finally Jeremy…

Poolbeg Pharma plc #POLB featured in The Pharma Times following this morning’s announcement on our exclusive licence signed with University of Warwick for broad spectrum #rna -based immunotherapy for respiratory virus infections… Full article here

17 January, 2022- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick. Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage. In vivo data confirms that this immunotherapy asset targets pan-respiratory virus infections, which…

Alan Green covers AEX Gold #AEXG and Poolbeg Pharma #POLB on this week’s Stockbox Research Talks

Poolbeg Pharma #POLB CEO Jeremy Skillington talks to BRR Media and outlines the progress made in the 5 months post IPO, along with group plans for 2022.

16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full licence and collaboration agreement to follow. The partnership allows Poolbeg exclusive access to AnaBio’s microencapsulation and nanoencapsulation technologies, IP and expertise for oral vaccine applications. Poolbeg will utilise this technology in conjunction with its own expertise in…

Alan Green joins the UK Investor Magazine Podcast to deliver his top stock picks for 2022. We touch briefly on the economic outlook for 2022 before delving into the companies Alan will be keeping a particularly close eye on next year. Top picks for 2022: Technology Minerals #TM1 Power Metal Resources #POW Blue Star Capital #BLU IQE #IQE Poolbeg Pharma #POLB Tertiary Minerals #TYM Special Mentions: Coinsilium #COIN Cadence Minerals #KDNC A number of these…

  Artificial Intelligence can play an exciting role in Infectious Disease drug discovery. Learn more about how #AI can deliver transformational data analysis in our recent article in @Pharmafocus , written by Liam Tremble, PhD Project Manager, R&D Operations https://bit.ly/31UZFbz

  #POLB featured in the Irish Times following the recently announced Option Agreement to licence #MelioVac with University College Dublin Potential to generate significant returns for investors Contributing to the global response to the threat of infectious diseases https://www.irishtimes.com/business/health-pharma/poolbeg-pharma-agrees-option-agreement-with-ucd-1.4747770

6 December 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor Siobhán McClean , through NovaUCD, the university’s knowledge transfer office.   The Company will continue its due diligence on MelioVac, a preclinical asset and recipient of a Wellcome Trust Award to aid its…

Take a look at this issue of shares spotlight which features Poolbeg Pharma on page 14-15.

25 November, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has appointed Professor Daniel Hoft to its Scientific Advisory Board . Prof Hoft, M.D., Ph.D. is the Dianna and J. Joseph Adorjan Endowed Chair of Infectious Diseases and Immunology, and Director of the Division of Infectious Diseases, Allergy & Immunology at Saint Louis University (SLU) School of Medicine. He has been working in immunology…

18 November 2021 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza. The Company intends to commence the Phase Ib human challenge study of POLB 001 in June 2022 which will be a key step in…

Poolbeg Pharma #POLB Exec Chairman Cathal Friel and CEO Jeremy Skillington talk to Alan Green about the company’s ‘capital light’ business model. We discuss the POLB 001 asset, spun out of Open Orphan #ORPH, data samples, the PredictViral and vaccine discovery platforms plus further pipeline products. Cathal discusses the company cash position, and Jeremy highlights the upcoming value inflection points for investors and shareholders.

    Alan Green talks about #VLG Venture Life Group, #POLB Poolbeg Pharma & #WOSG Watches of Switzerland on the Vox Market Podcast Listen to the Podcast here

Alan Green discusses ECR Minerals #ECR, with a tribute to CEO Craig Brown, plus Poolbeg Pharma #POLB on this week’s Stockbox Research talk

  4 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new patent filings for its PredictViral™ platform that estimates disease severity and contagiousness in people who are recently infected with a respiratory virus.   Expanding on existing PredictViral™ IP, these latest patent applications have been submitted in the UK and aims to protect a method…

RNA sequencing ahead of pioneering AI analysis programme 7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global biopharma services company, Eurofins Genomics (‘Eurofins’), to complete RNA sequencing for Poolbeg of Respiratory Syncytial Virus (RSV) disease progression samples from human viral challenge studies. This deep sequencing work is a key step leading to Poolbeg commencing…

7 September 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on the strengthening of its intellectual property (IP) position around lead product, POLB 001, a small molecule immunomodulator for the treatment of severe influenza. As detailed in the Admission Document, Poolbeg has a worldwide license for POLB 001 and is developing a strong IP portfolio with patent…

Poolbeg Pharma (AIM: POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model , is pleased to announce that admission of its entire issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker “POLB” and with the ISIN GB00BKPG7Z60 (“Admission”). The full Admission Document is available to view on the Company’s website at www.poolbegpharma.com…